Novel Antibody May Reduce Amyloid, Cut AD Symptoms

Lecanemab can reduce amyloid plaques within the first months after treatment initiation and is linked to improved clinical signs in as early as 6 months, updates from a phase 2 trial show.
Medscape Medical News

source https://www.medscape.com/viewarticle/971975?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost